Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

284 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Lung cancer.
Herbst RS, Heymach JV, Lippman SM. Herbst RS, et al. N Engl J Med. 2008 Sep 25;359(13):1367-80. doi: 10.1056/NEJMra0802714. N Engl J Med. 2008. PMID: 18815398 Review. No abstract available.
Farnesyl transferase inhibitors for patients with lung cancer.
Johnson BE, Heymach JV. Johnson BE, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4254s-4257s. doi: 10.1158/1078-0432.CCR-040016. Clin Cancer Res. 2004. PMID: 15217969 Review.
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF 3rd, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE. Heymach JV, et al. Ann Oncol. 2004 Aug;15(8):1187-93. doi: 10.1093/annonc/mdh315. Ann Oncol. 2004. PMID: 15277257 Clinical Trial.
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Davis DW, et al. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):678-89. Clin Cancer Res. 2005. PMID: 15701856
ZD6474--clinical experience to date.
Heymach JV. Heymach JV. Br J Cancer. 2005 Jun;92 Suppl 1(Suppl 1):S14-20. doi: 10.1038/sj.bjc.6602604. Br J Cancer. 2005. PMID: 15928653 Free PMC article. Review.
Emerging antiangiogenic agents in lung cancer.
Lee D, Heymach JV. Lee D, et al. Clin Lung Cancer. 2006 Mar;7(5):304-8. doi: 10.3816/CLC.2006.n.010. Clin Lung Cancer. 2006. PMID: 16640800 Review.
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Lynch TJ, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4365s-4371s. doi: 10.1158/1078-0432.CCR-06-1005. Clin Cancer Res. 2006. PMID: 16857812 No abstract available.
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Heymach JV, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4441s-4445s. doi: 10.1158/1078-0432.CCR-06-0286. Clin Cancer Res. 2006. PMID: 16857825 Review.
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. Engelman JA, et al. J Clin Invest. 2006 Oct;116(10):2695-706. doi: 10.1172/JCI28656. Epub 2006 Aug 10. J Clin Invest. 2006. PMID: 16906227 Free PMC article.
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Kamat AA, et al. Cancer Res. 2007 Jan 1;67(1):281-8. doi: 10.1158/0008-5472.CAN-06-3282. Cancer Res. 2007. PMID: 17210709
284 results
Jump to page
Feedback